910099-85-3

Upstream product

• 630-19-3 pivalaldehyde 
• 116907-30-3 (2R,5R)-2-(tert-butyl)-5-phenyl-1,3-dioxolan-4-one 
• 611-71-2 (R)-Mandelic Acid 
• 909298-90-4 (2R,5S)-2-(tert-butyl)-5-phenyl-5-(1-hydroxycyclopentyl)-1,3-dioxolan-4-one 

Downstream Products

• 114121-68-5 (R)-(-)-3-[(R)-2-hydroxy-2-cyclopentyl-2-phenylethoxy]-1-azabicyclo[2.2.2]octane 
• 852461-44-0 (R)-1-phenyl-1-cyclopentylethylene oxide 
• 910099-87-5 (R)-α-phenyl-α-cyclopentyl-α-hydroxyethyl p-toluenesulfonate 
• 183201-49-2 (R)-α-phenyl-α-cyclopentyl-α-hydroxyethanol 
• 936099-58-0 (R)-methyl-α-(cyclopentyl-1-ene)-α-hydroxy-α-phenylacetate 
• 64471-45-0 (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetic acid 
• 64471-47-2 (R)-α-phenyl-α-cyclopentyl-α-hydroxyacetate methyl ester 
• 244277-90-5 (2R,5R)-2-(tert-butyl)-5-phenyl-5-cyclopentyl-1,3-dioxolan-4-one 
• 185030-09-5 (R)-α-(cyclopentyl-1-ene)-α-hydroxyl-α-phenylacetic acid 

Relevant academic research and scientific papers

Discovery of a Novel Muscarinic Receptor PET Radioligand with Rapid Kinetics in the Monkey Brain

Positron emission tomography (PET), together with a suitable radioligand, is one of the more prominent methods for measuring changes in synaptic neurotransmitter concentrations in vivo. The radioligand of choice for such measurements on the cholinergic sy

A quaternary ammonium salt of pentethyl quinamidine optical isomer, pharmaceutical composition and its medical use

The invention relates to a quaternary ammonium salt compound shown as a formula I, or pharmaceutically acceptable salt or solvate thereof. The invention also relates to application of the compound as a selective M receptor antagonist, particularly a selec

Guanidine-containing compounds useful as muscarinic receptor antagonists

The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The in

Stereoselective synthesis of the optical isomers of a new muscarinic receptor antagonist, HL-031120

We present here a practical stereoselective synthetic method to produce enantiopure isomers of a new muscarinic receptor antagonist, HL-031120 (3-quinuclidinyl-2′-cyclopentyl-2′-hydroxy-2′-phenylacetate, I). Four optical isomers were effectively by stereoselective synthesized using pivaldehyde as steric hindrance agent from the chiral starting material, ( S ) or ( R )-mandelic acid. The isomers were obtained with 70-76% yields in 98-99% e.e. Copyright Taylor & Francis Group, LLC.

Stereoselective synthesis of the optical isomers of a new muscarinic receptor antagonist, quinuclidin-3-yl 2-(cyclopent-1-enyl)-2-hydroxy-2- phenylacetate

The enantiopure isomers of a new muscarinic receptor antagonist, quinuclidin-3-yl 2-(cyclopent-1-enyl)-2-hydroxy-2-phenylacetate were synthesised by a practical stereoselective synthetic method, using pivaldehyde as steric hindrance agent from the chiral starting material, (S) or (R)-mandelic acid. The isomers were obtained with 72-78% yields in 98-99% e.e.